TNDM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Tandem Diabetes Care Inc (TNDM) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are positive catalysts such as hedge fund buying and increased price targets from analysts, the technical indicators, financial performance, and legal risks suggest caution. Holding the stock for now may be a better approach until more clarity emerges.
The MACD is negatively expanding (-0.0452), indicating bearish momentum. RSI is neutral at 34.162, and moving averages are converging, showing no clear trend. The stock is trading near support levels (S1: 18.543), but there is no strong bullish signal.
Hedge funds are significantly increasing their positions (870.81% increase in buying last quarter). Analysts have raised price targets, with some projecting up to $35, citing strong demand, innovation, and expanding market opportunities.
Rosen Law Firm is investigating potential securities claims and preparing a class action lawsuit, which could weigh on investor sentiment. The stock has a history of volatility, with a 19.9% drop in August 2025 due to a medical device correction. Technical indicators are not showing strong bullish signals.
In Q3 2025, revenue grew by 2.17% YoY to $249.25M, but net income dropped by -8.97% YoY to -$21.17M. EPS declined by -11.43% YoY to -0.31. Gross margin improved to 53.88% (+5.46% YoY), but overall profitability remains a concern.
Analysts are mixed but leaning positive. Multiple firms raised price targets, with some projecting up to $35. However, there are concerns about near-term catalysts and high 2026 expectations. Ratings range from Hold to Buy, with some firms citing strong sector fundamentals and innovation as key drivers.
